These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 8487053)

  • 1. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
    Shimada Y; Yoshino M; Wakui A; Nakao I; Futatsuki K; Sakata Y; Kambe M; Taguchi T; Ogawa N
    J Clin Oncol; 1993 May; 11(5):909-13. PubMed ID: 8487053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
    Fukuoka M; Niitani H; Suzuki A; Motomiya M; Hasegawa K; Nishiwaki Y; Kuriyama T; Ariyoshi Y; Negoro S; Masuda N
    J Clin Oncol; 1992 Jan; 10(1):16-20. PubMed ID: 1309380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer].
    Nishimura G; Satou T; Yoshimitsu Y; Kurosaka Y; Fujimura T; Sugiyama K; Kanno M; Yonemura Y; Miwa K; Miyazaki I
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):93-7. PubMed ID: 7826085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer].
    Sakata Y; Shimada Y; Yoshino M; Kambe M; Futatsuki K; Nakao I; Ogawa N; Wakui A; Taguchi T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1039-46. PubMed ID: 8210255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
    Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
    J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].
    Negoro S; Fukuoka M; Niitani H; Suzuki A; Nakabayashi T; Kimura M; Motomiya M; Kurita Y; Hasegawa K; Kuriyama T
    Gan To Kagaku Ryoho; 1991 May; 18(6):1013-9. PubMed ID: 1851408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
    Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
    Pitot HC; Wender DB; O'Connell MJ; Schroeder G; Goldberg RM; Rubin J; Mailliard JA; Knost JA; Ghosh C; Kirschling RJ; Levitt R; Windschitl HE
    J Clin Oncol; 1997 Aug; 15(8):2910-9. PubMed ID: 9256135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
    Takeuchi S; Dobashi K; Fujimoto S; Tanaka K; Suzuki M; Terashima Y; Hasumi K; Akiya K; Negishi Y; Tamaya T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1681-9. PubMed ID: 1872624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
    Lavrenkov K; Man S; Mermershtain W; Cohen Y
    J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
    Verschraegen CF; Levy T; Kudelka AP; Llerena E; Ende K; Freedman RS; Edwards CL; Hord M; Steger M; Kaplan AL; Kieback D; Fishman A; Kavanagh JJ
    J Clin Oncol; 1997 Feb; 15(2):625-31. PubMed ID: 9053486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An early phase II study of CPT-11 in primary lung cancer].
    Nakai H; Fukuoka M; Furuse K; Nakao I; Yoshimori K; Ogura T; Hara N; Sakata Y; Saito H; Hasegawa K
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):607-12. PubMed ID: 1849391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
    Masuda N; Fukuoka M; Kusunoki Y; Matsui K; Takifuji N; Kudoh S; Negoro S; Nishioka M; Nakagawa K; Takada M
    J Clin Oncol; 1992 Aug; 10(8):1225-9. PubMed ID: 1321891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CPT-11: the European clinical development.
    Terret C; Couteau C; Armand JP
    J Infus Chemother; 1996; 6(3):152-7. PubMed ID: 9229329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
    Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
    Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].
    Taguchi T; Tominaga T; Ogawa M; Ishida T; Morimoto K; Ogawa N
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1017-24. PubMed ID: 8210251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.